Autori: Meng Ling Choong, Christian Pecquet, Vishal Pendharkar, Carmen C. Diaconu, Jacklyn Wei Yan Yong. Shi Jing Tai, Si Fang Wang, Jean-Philippe Defour, Kanda Sangthongpitag, Jean-Luc Villeval, William Vainchenker, Stefan N. Constantinescu, May Ann Lee

Editorial: Wiley, Journal of Cellular and Molecular Medicine, 17 (11), p.1397 - 140, 2013.

Rezumat:

Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiological JAK2 signalling. We tested whether combining a JAK2 inhibitor with a series of serine threonine kinase inhibitors, targeting nine signalling pathways and already used in clinical trials, synergized in inhibiting growth of haematopoietic cells expressing mutant and wild-type forms of JAK2 (V617F) or thrombopoietin receptor (W515L). Out of 15 kinase inhibitors, the ZSTK474 phosphatydylinositol-3′-kinase (PI3K) inhibitor molecule showed strong synergic inhibition by Chou and Talalay analysis with JAK2 and JAK2/JAK1 inhibitors. Other pan-class I, but not gamma or delta specific PI3K inhibitors, also synergized with JAK2 inhibitors. Synergy was not observed in Bcr-Abl transformed cells. The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F. It also exerted strong inhibitory effects on erythropoietin-independent erythroid colonies from MPN patients and JAK2 V617F knock-in mice, where at certain doses, a preferential inhibition of JAK2 V617F mutated progenitors was detected. Our data support the use of a combination of JAK2 and pan-class I PI3K inhibitors in the treatment of MPNs.

Cuvinte cheie: JAK2, PI3K, combination treatment, kinases, myeloproliferative neoplasms

URL: http://onlinelibrary.wiley.com/doi/10.1111/jcmm.12156/pdf